WASHINGTON — Sen. Bill Cassidy (R-La.) is pitching Democrats on his compromise to make Affordable Care Act marketplace plans ...
A new analysis finds medicines often are not accessible countries where they were tested before approval by the FDA, raising ...
Johnson & Johnson said it will purchase Halda Therapeutics, marking the first major buyout for a cancer drugmaker built ...
Despite widespread skepticism, the National Science Foundation and DARPA have invested millions of dollars in organoid-based ...
Over 74,000 people enrolled in experiments have been affected by the NIH's funding cuts, according to a new report.
WuXi AppTec, the Chinese pharma giant with extensive ties with U.S. companies, appears to be thriving now that the threat of ...
The toll from cervical cancer is highest in lower-income countries, which often lack screening programs that can result in ...
Novo Nordisk has begun selling Wegovy for $349 a month to cash payers, months ahead of the timeline set out with the Trump ...
Johnson & Johnson said it is acquiring Halda Therapeutics, a developer of cancer drugs, for $3.05 billion. Halda’s lead ...
Nuvalent said its drug for ALK+ lung cancer shrank tumors in more than a quarter of patients whose disease had returned after ...
ROAI isn't about flashy demos or model size. It's about measurable improvements,” writes Sanofi CEO Paul Hudson.
The FDA has cleared home use of a device that helps people with spinal cord injuries regain mobility and functioning.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback